索利那新聯(lián)合依帕司他治療2型糖尿病合并膀胱過度活動癥的療效觀察
發(fā)布時間：2018-07-16 20:51
【摘要】：目的觀察索利那新聯(lián)合依帕司他治療T2DM合并膀胱過度活動癥(OAB)的療效和安全性。方法選取T2DM合并OAB患者80例,隨機分為對照組(Con)24例,依帕司他組29例,索利那新+依帕司他組27例。Con組予常規(guī)膀胱訓練、降糖、降壓、調(diào)脂、營養(yǎng)神經(jīng)等一般治療。在一般治療的基礎(chǔ)上,依帕司他組口服依帕司他50 mg,3次/d。索利那新+依帕司他組口服索利那新5 mg,1次/d,依帕司他50 mg,3次/d。觀察12周,記錄排尿日記、OAB自我評價量表(OABSS)評分、最大尿流率(Qmax)、平均尿流率(Qave)、排尿量(VV)。結(jié)果索利那新+依帕司他組治療后24 h排尿次數(shù)、夜尿次數(shù)、尿急次數(shù)、尿失禁次數(shù)、OABSS評分均低于Con組和依帕司他組,Qmax、Qave、VV高于Con組和依帕司他組(P0.05);依帕司他組治療后OABSS評分低于Con組,VV高于Con組(P0.05);索利那新+依帕司他組總有效率高于依帕司他組和Con組(92.6%vs69.0%vs41.7%,P0.05)。結(jié)論索利那新聯(lián)合依帕司他治療T2DM合并OAB的療效確切。
[Abstract]:Objective To observe the efficacy and safety of corelna combined with esprolac in the treatment of T2DM combined with hyperactivity of bladder (OAB). Methods 80 patients with OAB were randomly divided into 24 cases of control group (Con), 29 cases in the group of esproactive and 27 cases of group.Con in group.Con of corelna + elaxin and the group of IVA. In general treatment, on the basis of general treatment, the group of the IVA group took orally 50 mg of IVA, 3 /d. corelino + elaxin group, 1 /d, 50 mg and 3 /d. for 12 weeks, recorded the diaries of urination, OAB self evaluation scale (OABSS) score, maximum urinary flow rate (Qmax), average urinary flow rate (Qave), urination volume (VV). The number of urinating times, the number of nocturnal times, the times of urination, the frequency of urination, the number of incontinence, and the OABSS score of the group of 24 h after the treatment were lower than that of group Con and the group of the IVA, Qmax, Qave, VV were higher than that of the Con group and the group of the IVA (P0.05); the OABSS score of the IVA group was lower than the Con group, and the VV was higher than that of the Con group. The rate was higher than that of the Con group (92.6%vs69.0%vs41.7%, P0.05). Conclusion the efficacy of the combination of orlistat and ellistat is effective in the treatment of T2DM complicated with OAB.
【作者單位】： 遼寧省人民醫(yī)院內(nèi)分泌科;青海省湟中縣人民醫(yī)院內(nèi)三科;
【分類號】：R587.2;R694.5
[Abstract]:Objective To observe the efficacy and safety of corelna combined with esprolac in the treatment of T2DM combined with hyperactivity of bladder (OAB). Methods 80 patients with OAB were randomly divided into 24 cases of control group (Con), 29 cases in the group of esproactive and 27 cases of group.Con in group.Con of corelna + elaxin and the group of IVA. In general treatment, on the basis of general treatment, the group of the IVA group took orally 50 mg of IVA, 3 /d. corelino + elaxin group, 1 /d, 50 mg and 3 /d. for 12 weeks, recorded the diaries of urination, OAB self evaluation scale (OABSS) score, maximum urinary flow rate (Qmax), average urinary flow rate (Qave), urination volume (VV). The number of urinating times, the number of nocturnal times, the times of urination, the frequency of urination, the number of incontinence, and the OABSS score of the group of 24 h after the treatment were lower than that of group Con and the group of the IVA, Qmax, Qave, VV were higher than that of the Con group and the group of the IVA (P0.05); the OABSS score of the IVA group was lower than the Con group, and the VV was higher than that of the Con group. The rate was higher than that of the Con group (92.6%vs69.0%vs41.7%, P0.05). Conclusion the efficacy of the combination of orlistat and ellistat is effective in the treatment of T2DM complicated with OAB.
【作者單位】： 遼寧省人民醫(yī)院內(nèi)分泌科;青海省湟中縣人民醫(yī)院內(nèi)三科;
【分類號】：R587.2;R694.5
【相似文獻】
相關(guān)期刊論文 前10條
1 班春梅;艾菊;喻，
本文編號：2127635
本文鏈接：http://sikaile.net/yixuelunwen/nfm/2127635.html
最近更新
教材專著
